The company’s presentation, which becomes available for digital access on September 11, 2026, outlines the firm's progress in developing RapaGlues. These macrocyclic inhibitors, born from the Johns Hopkins laboratory of Dr. Jun O. Liu, function by forming ternary complexes that modulate challenging disease targets, including transcription factors and transmembrane receptors.

Rapafusyn currently utilizes a combination of DNA-encoded and arrayed libraries to identify candidates that demonstrate cell permeability and high selectivity. By targeting protein-protein interactions that have historically eluded traditional drug discovery, the firm aims to address high unmet clinical needs. Investors and industry stakeholders can access the overview via the company’s website ahead of the physical conference, which runs from September 14–15 in New York.